Investors watching AbbVie Inc. (NYSE: ABBV) have increasingly circled one round-number objective: $300. The North Chicago–based biopharmaceutical giant has spent much of the past year trading in a range that peaked near $267, and shares recently hovered around the $255 mark. With several Wall Street firms publishing or maintaining $300 targets in 2026, the question of whether AbbVie can actually reach that level has moved from hypothetical to genuinely discussed. The answer is not a simple yes or no — it hinges on whether the company's post-Humira growth engines can keep compounding while investors accept a richer valuation.
The $300 level is meaningful for two reasons. First, it is a psychological round number that has emerged repeatedly in analyst commentary. Second, it sits comfortably above the stock's prior 52-week high near $267, meaning it represents a genuine breakout target rather than a level that has already been tested. Multiple firms have anchored their models around this figure: BMO Capital and Wells Fargo have both set or maintained $300 targets, while HSBC went further, lifting its objective to $315. That concentration of Street targets makes $300 the most widely discussed intermediate milestone for the stock.
AbbVie's post-Humira narrative is anchored by two blockbuster immunology franchises. Skyrizi and Rinvoq together have come to represent roughly half of the company's revenue, cushioning the decline of Humira, which lost U.S. patent protection in 2023. A legal settlement delaying Rinvoq's U.S. generic competition until 2037 has removed a major overhang and extended the drug's growth runway well into the next decade.
Beyond immunology, AbbVie has a diversified portfolio spanning oncology, neuroscience, aesthetics, and eye care. Products such as Vraylar and a deep clinical pipeline offer multiple avenues for future catalysts. A beat-and-raise third-quarter earnings report in 2025 — supported by Skyrizi and Rinvoq strength — reinforced the view that management can keep raising guidance as the Humira erosion fades into the background. If the company continues delivering revenue growth in the high-single to low-double digits, the path toward a $300 share price becomes more plausible.
The clearest obstacle is valuation. AbbVie's stock has already re-rated meaningfully, and its price-to-earnings (P/E) ratio reflects elevated expectations. That leaves less room for multiple expansion, meaning future gains must come primarily from earnings growth rather than sentiment. If growth slows or if Skyrizi and Rinvoq face sharper-than-expected competition — including from newer oral immunology entrants — the stock could stall well short of $300.
Ongoing softness in the aesthetics segment and the steady decline of Humira revenue also remain drags. While these headwinds are well understood, any disappointment in quarterly results or pipeline readouts could quickly reset the market's enthusiasm. Some firms have already shifted to neutral stances, citing a more balanced risk-reward profile at current levels.
The analyst consensus on AbbVie is broadly constructive. According to data compiled by S&P Global, the stock carries a consensus "Buy" rating with an average one-year price target near $277. The range is wide, however, spanning from a low of $200 to a high of $328. Individual targets cluster around the $280–$300 area, with HSBC at $315, BMO and Wells Fargo at $300, and firms such as Bank of America, TD Cowen, and RBC Capital in the $280–$282 range. That means a $300 objective sits above the consensus average but within the span of several prominent bullish forecasts — consistent with the idea that reaching $300 is possible but would require the company to deliver on the more optimistic end of expectations.
From a technical analysis standpoint, the stock has established a meaningful support zone near $245–$250, an area that previously acted as a consolidation floor. On the upside, the prior 52-week high around $267 represents the first significant resistance level and supply zone. A decisive break and hold above that level would remove the most immediate barrier and open the door to a push toward $300. Until then, $267 stands as the key level separating a continued range-bound market from a genuine breakout.
Traders monitoring AbbVie's progress toward its price target can supplement their own analysis with tools such as Tickeron's AI Daily Buy/Sell Signals. This product uses artificial intelligence to continuously monitor thousands of stocks and exchange-traded funds, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. These signals are designed to help traders discover emerging opportunities, monitor existing positions, and identify changing market trends more efficiently than manual screening alone. For investors tracking a potential move toward $300, such tools can provide a timely, data-driven complement to fundamental research.
Reaching $300 is a realistic but demanding objective for AbbVie. The supportive case rests on the continued strength of Skyrizi and Rinvoq, the extended Rinvoq exclusivity, and a diversified pipeline that could keep growth compounding. The primary risks are a valuation that already reflects much of the optimism, lingering Humira erosion, and competitive threats in immunology and aesthetics. Investors should watch the $267 prior-high resistance level, quarterly growth trends in the core immunology franchise, and any pipeline readouts that could shift the fundamental picture. A decisive break above $267 would materially improve the odds of a run toward $300, while failure to hold the $245–$250 support zone would suggest the target remains out of reach for now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with BMY. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | -0.02% | ||
| BMY - ABBV | 51% Loosely correlated | +0.35% | ||
| NVS - ABBV | 50% Loosely correlated | -0.39% | ||
| JNJ - ABBV | 49% Loosely correlated | -0.09% | ||
| MRK - ABBV | 46% Loosely correlated | -0.19% | ||
| AMGN - ABBV | 46% Loosely correlated | +1.55% | ||
More | ||||